Sagent Pharmaceuticals 10-Q 5 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'SGNT	'
Entity Registrant Name	'SAGENT PHARMACEUTICALS, INC.	'
Entity Central Index Key	'0001369786	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	31,910,255

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$136,280	$42,332
Short-term investments	18,995	113,810
Accounts receivable, net of chargebacks and other deductions	33,880	23,033
Inventories, net	43,301	46,481
Due from related party	2,716	3,644
Prepaid expenses and other current assets	4,598	6,491
Total current assets	239,770	235,791
Property, plant, and equipment, net	56,859	57,684
Investment in joint ventures	4,539	2,063
Goodwill	6,038	6,038
Intangible assets, net	9,050	8,326
Other assets	309	306
Total assets	316,565	310,208
Current liabilities:	'	'
Accounts payable	27,314	24,010
Due to related party	7,528	3,129
Accrued profit sharing	7,231	8,740
Accrued liabilities	14,137	13,931
Current portion of deferred purchase consideration	8,624	3,381
Current portion of long-term debt	'	10,333
Total current liabilities	64,834	63,524
Long term liabilities:	'	'
Long-term portion of deferred purchase consideration	'	8,329
Other long-term liabilities	1,981	2,329
Total liabilities	66,815	74,182
Stockholders' equity:	'	'
Common stock-$0.01 par value, 100,000,000 authorized and 31,899,410 and 28,192,824 outstanding at September 30, 2014 and December 31, 2013, respectively	319	318
Additional paid-in capital	353,358	349,278
Accumulated other comprehensive income	17	487
Accumulated deficit	-103,944	-114,057
Total stockholders' equity	249,750	236,026
Total liabilities and stockholders' equity	$316,565	$310,208

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common stock, par value	$0.01	$0.01
Common stock, authorized shares	100,000,000	100,000,000
Common stock, outstanding shares	31,899,410	28,192,824

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenue	$65,359	$60,842	$205,422	$180,644
Cost of sales	46,589	42,255	143,676	120,381
Gross profit	18,770	18,587	61,746	60,263
Operating expenses:	'	'	'	'
Product development	3,677	6,888	17,734	15,629
Selling, general and administrative	10,914	9,083	31,622	26,030
Acquisition-related costs	872	'	872	'
Equity in net (income) loss of joint ventures	-737	-485	-2,476	118
Total operating expenses	14,726	15,486	47,752	41,777
Termination fee	'	'	'	5,000
Gain on previously held equity interest	'	'	'	2,936
Income from operations	4,044	3,101	13,994	26,422
Interest income and other income (expense)	-536	44	-465	94
Interest expense	-195	-319	-641	-482
Income before income taxes	3,313	2,826	12,888	26,034
Provision for income taxes	1,387	'	2,774	'
Net income	$1,926	$2,826	$10,114	$26,034
Net income per common share:	'	'	'	'
Basic	$0.06	$0.10	$0.32	$0.92
Diluted	$0.06	$0.10	$0.31	$0.90
Weighted-average of shares used to compute net income per common share:	'	'	'	'
Basic	31,895	28,745	31,861	28,349
Diluted	32,960	29,568	32,748	29,051

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net income	$1,926	$2,826	$10,114	$26,034
Other comprehensive income (loss), net of tax	'	'	'	'
Foreign currency translation adjustments	-2	170	-448	464
Reclassification of cumulative currency translation gain	'	'	'	-2,782
Reclassification of unrealized losses on available for sale securities	49	'	49	'
Unrealized gains (losses) on available for sale securities	-101	21	-22	-71
Total other comprehensive income (loss), net of tax	-54	191	-421	-2,389
Comprehensive income	$1,872	$3,017	$9,693	$23,645

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities	'	'
Net income	$10,114	$26,034
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	6,307	4,166
Stock-based compensation	3,657	4,230
Equity in net (income) loss of joint ventures	-2,476	118
Dividends from unconsolidated joint venture	'	1,995
Gain on previously held equity interest	'	-2,936
Other	-200	'
Changes in operating assets and liabilities, net of effect of acquisition:	'	'
Accounts receivable, net	-10,848	6,818
Inventories	3,180	892
Prepaid expenses and other current assets	1,887	-4,435
Due from related party	-728	-6,261
Accounts payable and other accrued liabilities	8,574	1,128
Net cash provided by operating activities	19,467	31,749
Cash flows from investing activities	'	'
Capital expenditures	-2,875	-783
Acquisition of business, net of cash acquired	-3,500	-7,296
Investments in unconsolidated joint ventures	'	-19
Purchases of investments	-80,998	-220,719
Sale of investments	174,722	146,528
Purchase of product rights	-2,863	-2,364
Net cash provided by (used in) investing activities	84,486	-84,653
Cash flows from financing activities	'	'
Reduction in short-term notes payable	-10,324	'
Proceeds from issuance of common stock, net of issuance costs	425	71,158
Payment of deferred financing costs	-75	-28
Net cash (used in) provided by financing activities	-9,974	71,130
Effect of exchange rate movements on cash	-31	24
Net increase in cash and cash equivalents	93,948	18,250
Cash and cash equivalents, at beginning of period	42,332	27,687
Cash and cash equivalents, at end of period	$136,280	$45,937

Basis_of_presentation

Basis of presentation	9 Months Ended
	Sep. 30, 2014
Basis of presentation	'
	Note 1. Basis of presentation:
	Our interim condensed consolidated financial statements are unaudited. We prepared the condensed consolidated financial statements following rules for interim reporting as prescribed by the U.S. Securities and Exchange Commission (“SEC”). As permitted under those rules, we have condensed or omitted a number of footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). It is management’s opinion that these financial statements include all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of our financial position, operating results and cash flows. Operating results for any interim period are not necessarily indicative of future or annual results.
	We are organized as a single reportable segment comprised of operations which develop, source and market generic injectable products for sale in the United States, deriving a significant portion of our revenues from a single class of pharmaceutical wholesale customers in the United States.
	The condensed consolidated financial statements include Sagent as well as our wholly owned subsidiaries as of the dates and for the periods presented. All material intercompany balances and transactions have been eliminated in consolidation. We account for our 50% investment in Sagent Agila LLC (formerly Sagent Strides LLC) using the equity method of accounting, as our interest in the entity provides for joint financial and operational control.
	In June 2013, we acquired the remaining 50% interest in Kanghong Sagent (Chengdu) Pharmaceutical Co., Ltd. (“KSCP”), which we subsequently renamed Sagent (China) Pharmaceuticals Co., Ltd. (“SCP”), from our former joint venture partner. Accordingly, commencing as of June 30, 2013, our condensed consolidated financial statements include SCP as a wholly-owned subsidiary. Prior to the acquisition, we accounted for our investment in KSCP using the equity method of accounting, as our interest in the entity provided for joint financial and operational control.
	Certain amounts previously included in accounts payable have been reclassified to accrued liabilities to conform to the current period presentation.
	You should read these statements in conjunction with our consolidated financial statements and related notes for the year ended December 31, 2013, included in our Annual Report on Form 10-K filed with the SEC on March 7, 2014.
	New accounting standards
	In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. We are required to adopt this new guidance on January 1, 2017, using one of two prescribed retroactive methods. Early adoption is not permitted. We are evaluating the impact of the amended revenue recognition guidance on our consolidated financial statements.

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2014
Acquisition	'
	Note 2. Acquisition:
	Remaining equity interest of SCP
	On June 4, 2013, we acquired Chengdu Kanghong Pharmaceuticals (Group) Co. Ltd (“CKT”) 50% equity interest in KSCP for $25,000, payable in installments through September 2015. We acquired net tangible assets consisting of cash of $2,704, inventory of $2,396, prepaid assets of $196, and property, plant and equipment of $56,654, net of assumed liabilities, primarily long term bank loans of $19,095 and accrued compensation and other liabilities of $8,954. We recorded goodwill of $6,038 due to the synergies achieved by having control over the products and manufacturing at the SCP facility.
	In September 2014, we made a $3,500 installment payment related to this acquisition. The remaining $9,000 installment is required to be paid by September 2015.
	Product rights acquisitions
	On December 12, 2013, we acquired two product rights, Mesna and Acetylcysteine, owned by Sagent Agila pursuant to an agreement with Mylan Inc. The total fair value of consideration transferred was $3,400, consisting of $3,200 of cash and $200 of contingent consideration
	The following unaudited pro forma financial information reflects the consolidated results of operations of Sagent as if these acquisitions had taken place on January 1, 2013. The pro forma information includes acquisition and integration expenses. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.
		Three Months Ended		Nine Months Ended
		September 30, 2013		September 30, 2013
	Net revenue	$	60,842	$	180,644
	Net income		2,826		19,405
	Diluted income per common share		0.1		0.67
	On October 1, 2014 we acquired all of the issued and outstanding shares of the capital stock of Omega Laboratories Limited and 7685947 Canada Inc. (collectively, “Omega”), a privately held Canadian pharmaceutical and specialty healthcare products company. The Omega acquisition is described in greater detail in Note 19. Subsequent Events.

Investments

Investments	9 Months Ended
	Sep. 30, 2014
Investments	'
	Note 3. Investments:
	Our investments at September 30, 2014 were comprised of the following:
		Cost basis		Unrealized			Unrealized			Recorded		Cash and		Short term
				gains			losses			basis		cash		investments
												equivalents
	Assets
	Cash	$	123,647	$	—		$	—		$	123,647	$	123,647	$	—
	Money market funds		12,633		—			—			12,633		12,633		—
	Commercial paper		5,530		—			—			5,530		—		5,530
	Corporate bonds and notes		13,496		1			(32	)		13,465		—		13,465
		$	155,306	$	1		$	(32	)	$	155,275	$	136,280	$	18,995
	Investments with continuous unrealized losses for less than twelve months and their related fair values at September 30, 2014 were as follows:
		Fair value		Unrealized
				losses
	Corporate bonds and notes	$	11,355	$	(32	)
	Commercial paper		2,530		—
		$	13,885	$	(32	)
	Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. Because we do not currently intend to sell these investments, and it is not more likely than not that we will be required to sell our investments before recovery of their amortized cost basis, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at September 30, 2014.
	The original cost and estimated current fair value of our fixed-income securities at September 30, 2014 are set forth below.
		Cost basis		Estimated fair
				value
	Due in one year or less	$	9,670	$	9,671
	Due between one and five years		9,356		9,324
		$	19,026	$	18,995

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventories	'
	Note 4. Inventories:
	Inventories at September 30, 2014 and December 31, 2013 were as follows:
		September 30, 2014								December 31, 2013
		Approved			Pending		Inventory			Approved			Pending			Inventory
					regulatory								regulatory
					approval								approval
	Finished goods	$	40,136		$	—	$	40,136		$	44,510		$	1,437		$	45,947
	Raw materials		5,305			2,803		8,108			5,614			19			5,633
	Inventory reserve		(4,943	)		—		(4,943	)		(3,662	)		(1,437	)		(5,099	)
		$	40,498		$	2,803	$	43,301		$	46,462		$	19		$	46,481

Property_plant_and_equipment

Property, plant and equipment	9 Months Ended
	Sep. 30, 2014
Property, plant and equipment	'
	Note 5. Property, plant and equipment
	Property, plant and equipment at September 30, 2014 and December 31, 2013 were as follows:
		September 30,			December 31,
		2014			2013
	Land and land improvements	$	2,215		$	2,235
	Buildings and improvements		19,519			19,696
	Machinery, equipment, furniture and fixtures		38,447			38,000
	Construction in process		2,558			460
			62,739			60,391
	Less accumulated depreciation		(5,880	)		(2,707	)
		$	56,859		$	57,684
	Depreciation expense was $701 and $2,698 for the three and nine months ended September 30, 2014, respectively.

Goodwill_and_Intangible_assets

Goodwill and Intangible assets, net	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible assets, net	'
	Note 6. Goodwill and Intangible assets, net:
	Goodwill at September 30, 2014 and December 31, 2013 was $6,038, which was recorded in connection with our acquisition of the remaining equity interest in KSCP in June 2013. There were no reductions of goodwill relating to impairments for the three and nine months ended September 30, 2014.
	Intangible assets at September 30, 2014 and December 31, 2013 were as follows:
		September 30, 2014								December 31, 2013
		Gross carrying			Accumulated			Intangible		Gross carrying		Accumulated			Intangible
		amount			amortization			assets, net		amount		amortization			assets, net
	Product licensing rights	$	6,748		$	(2,750	)	$	3,998	$	5,941	$	(2,087	)	$	3,854
	Product development rights		3,832			—			3,832		3,252		—			3,252
	Total definite-lived intangible assets	$	10,580		$	(2,750	)	$	7,830	$	9,193	$	(2,087	)	$	7,106
	In-process research and development (IPR&D)	$	1,220		$	—		$	1,220	$	1,220	$	—		$	1,220
	Total intangible assets	$	11,800		$	(2,750	)	$	9,050	$	10,413	$	(2,087	)	$	8,326
	Changes in intangible assets were due to the following:
		Product			Product			IPR&D
		licensing			development
		rights			rights
	December 31, 2013	$	3,854		$	3,252		$	1,220
	Purchase of product rights		810			2,053			—
	Amortization of product rights		(666	)		(1,473	)		—
	September 30, 2014	$	3,998		$	3,832		$	1,220
	The weighted-average period prior to the next extension or renewal for the 27 products comprising our product licensing rights intangible asset was 69 months at September 30, 2014.
	We currently estimate amortization expense over each of the next five years as follows:
		Amortization
		expense
	For the year ending:
	September 30, 2015	$	4,512
	September 30, 2016	$	693
	September 30, 2017	$	609
	September 30, 2018	$	600
	September 30, 2019	$	533

Investment

Investment (Sagent Agila LLC)	9 Months Ended
	Sep. 30, 2014
Sagent Agila LLC	'
Investment	'
	Note 7. Investment in Sagent Agila:
	Changes in our investment in Sagent Agila during the nine months ended September 30, 2014 were as follows:
	Investment in Sagent Agila at January 1, 2014	$	2,063
	Equity in net income of Sagent Agila		2,476
	Investment in Sagent Agila at September 30, 2014	$	4,539
	Condensed statement of operations information of Sagent Agila is presented below.
		Three Months Ended September 30,				Nine Months Ended September 30,
	Condensed statement of operations information	2014		2013		2014		2013
	Net revenues	$	1,516	$	3,212	$	6,249	$	13,924
	Gross profit		1,473		1,093		4,992		3,817
	Net income		1,473		969		4,952		3,413

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt	'
	Note 8. Debt:
	SCP credit facilities
	In connection with the acquisition of the remaining 50% equity interest in SCP in June 2013, we assumed two loan contracts with the Agricultural Bank of China Ltd. in the amount of RMB 37,000 ($6,069) and RMB 83,000 ($13,613) originally entered into in June 2011 and August 2010, respectively, (the “ABC Loans”) each with a five year term. Amounts outstanding under the ABC Loans bore an interest rate equal to the benchmark lending interest rate published by the People’s Bank of China, subject to adjustment every three months. As the interest rate resets on a quarterly basis, the fair value of our long-term debt approximated its carrying value. As of December 31, 2013 RMB 63,000 ($10,333) was outstanding under the ABC Loans. On January 2, 2014, we repaid in full the then-outstanding balance of the ABC Loans, totaling RMB 63,000 ($10,333). Upon prepayment of the ABC Loans, the loan contracts were terminated. No early termination fees were incurred as part of the prepayment of the ABC Loans.

Accrued_liabilities

Accrued liabilities	9 Months Ended
	Sep. 30, 2014
Accrued liabilities	'
	Note 9. Accrued liabilities:
	Accrued liabilities at September 30, 2014 and December 31, 2013 were as follows:
		September 30,		December 31,
		2014		2013
	Payroll and employee benefits	$	5,595	$	6,224
	Sales and marketing		5,015		5,305
	Taxes payable		1,564		895
	Other accrued liabilities		1,963		1,507
		$	14,137	$	13,931

Fair_value_measurements

Fair value measurements	9 Months Ended
	Sep. 30, 2014
Fair value measurements	'
	Note 10. Fair value measurements:
	Assets measured at fair value on a recurring basis as of September 30, 2014 consisted of the following:
		Total fair value			Quoted prices in		Significant other		Significant
					active markets		observable		unobservable
					for identical		inputs (Level 2)		inputs
					assets (Level 1)				(Level 3)
	Assets
	Money market funds	$	12,633		$	12,633	$	—	$	—
	Corporate bonds and notes		13,465			—		13,465		—
	Commercial paper		5,530			—		5,530		—
	Short-term investments	$	18,995		$	—	$	18,995	$	—
	Total assets	$	31,628		$	12,633	$	18,995	$	—
	Liabilities
	Contingent purchase consideration	$	—		$	—	$	—	$	—
	Assets measured at fair value on a recurring basis as of December 31, 2013 consisted of the following:
		Total fair value			Quoted prices in		Significant other		Significant
					active markets		observable		unobservable
					for identical		inputs (Level 2)		inputs
					assets (Level 1)				(Level 3)
	Assets
	Money market funds	$	11,592		$	11,592	$	—	$	—
	Corporate bonds and notes		92,516			—		92,516		—
	Commercial paper		21,294			—		21,294		—
	Short-term investments	$	113,810		$	—	$	113,810	$	—
	Total assets	$	125,402		$	11,592	$	113,810	$	—
	Liabilities
	Contingent purchase consideration	$	200		$	—	$	—	$	200
	The fair value of our Level 2 investments is based on a combination of quoted market prices of similar securities and matrix pricing provided by third-party pricing services utilizing securities of similar quality and maturity. The fair value of our Level 3 contingent consideration is based upon a probability weighting approach that considered the possible outcomes based on assumptions related to the timing and probability of the product approval date.
	There were no transfers of assets between Level 1, Level 2 or Level 3 during the periods presented.
	Changes in the fair value of our contingent purchase consideration measured using significant unobservable inputs (Level 3), during the nine months ending September 30, 2014 were as follows:
	Balance at January 1, 2014	$	200
	Issuance of contingent purchase consideration		—
	Change in fair value of contingent purchase consideration		(200	)
	Payment of contingent purchase consideration		—
	Balance at September 30, 2014	$	—

Accumulated_other_comprehensiv

Accumulated other comprehensive income	9 Months Ended
	Sep. 30, 2014
Accumulated other comprehensive income	'
	Note 11. Accumulated other comprehensive income:
	Accumulated other comprehensive income at September 30, 2014 and December 31, 2013 is comprised of the following:
		September 30,			December 31,
		2014			2013
	Currency translation adjustment, net of tax	$	48		$	496
	Unrealized gains (losses) on available for sale securities, net of tax		(31	)		(9	)
	Total accumulated other comprehensive income	$	17		$	487
	During the three and nine months ended September 30, 2014, $49 of realized losses on available for sale securities, which have been included in interest income and other income (expense) in the condensed consolidated statements of operations, was reclassified from accumulated other comprehensive income based on the specific identification method.

Earnings_per_share

Earnings per share	9 Months Ended
	Sep. 30, 2014
Earnings per share	'
	Note 12. Earnings per share:
	Basic earnings per share is calculated by dividing net income available to common stockholders by the weighted average number of common shares outstanding for the period. Because of their anti-dilutive effect, the following common share equivalents, comprised of restricted stock and unexercised stock options, have been excluded from the calculation of diluted earnings per share for the three and nine month periods ended September 30, 2014 and 2013, respectively:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Anti-dilutive shares (in thousands)		435		923		1,124		1,212
	The table below presents the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Basic and dilutive numerator:
	Net income, as reported	$	1,926	$	2,826	$	10,114	$	26,034
	Denominator:
	Weighted-average common shares outstanding - basic (in thousands)		31,895		28,745		31,861		28,349
	Net effect of dilutive securities:
	Stock options and restricted stock		1,065		823		887		702
	Weighted-average common shares outstanding - diluted (in thousands)		32,960		29,568		32,748		29,051
	Net income per common share (basic)	$	0.06	$	0.1	$	0.32	$	0.92
	Net income per common share (diluted)	$	0.06	$	0.1	$	0.31	$	0.9

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Stock-Based Compensation	'
	Note 13. Stock-based compensation:
	The table below presents the change in stock options, restricted stock units (RSUs) and restricted stock awards (RSAs) for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Stock options (in thousands):
	Stock options granted		2		5		261		380
	Stock options exercised		16		29		90		96
	Aggregate intrinsic value of stock options exercised (in thousands)	$	319	$	489	$	1,522	$	1,225
	Restricted Stock Units (RSUs) (in thousands):
	RSUs granted		—		—		19		15
	Restricted Stock Awards (RSAs) (in thousands):
	RSAs granted		—		—		48		42

Net_Revenue_by_Product

Net Revenue by Product	9 Months Ended
	Sep. 30, 2014
Net Revenue by Product	'
	Note 14. Net revenue by product:
	Net revenue by product line is as follows:
		Three Months Ended September 30,				Nine Months Ended September 30,
	Therapeutic class:	2014		2013		2014		2013
	Anti-infective	$	21,370	$	24,026	$	74,896	$	65,921
	Critical care		21,530		15,638		62,153		48,381
	Oncology		22,459		21,178		68,373		66,342
		$	65,359	$	60,842	$	205,422	$	180,644

Related_party_transactions

Related party transactions	9 Months Ended
	Sep. 30, 2014
Related party transactions	'
	Note 15. Related party transactions:
	As of September 30, 2014 and December 31, 2013, respectively, we had a receivable of $2,716 and $3,644 from Sagent Agila LLC, which is expected to offset future profit-sharing payments. As of September 30, 2014 and December 31, 2013, respectively, we had a payable of $7,528 and $3,129 to Sagent Agila LLC, principally for the acquisition of inventory and amounts due under profit-sharing arrangements. There were no profit sharing receipts distributed to Sagent Agila LLC’s joint venture partners during the nine months ended September 30, 2014.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Taxes	'
	Note 16. Income Taxes:
	2014 tax provision
	Our provision for income taxes for the three and nine months ended September 30, 2014 was $1,387 and $2,774 respectively. Our provision for income taxes represents the alternative minimum tax (“AMT”) payable in the United States for 2014 and $933 in both the three and nine months ended September 30, 2014, respectively, of income taxes payable related to certain states where we believe, due to changes in current facts and circumstances, the probable outcome of our tax filing position, if audited, has changed. As we have recorded a full valuation allowance against our net domestic deferred tax assets, our AMT payable is recorded as tax expense.
	Valuation Allowance
	We recorded a full valuation allowance in 2007 due to our cumulative loss position at that time. At September 30, 2014, we had approximately a $25,000 valuation allowance established against our domestic deferred income tax assets, which represents a full valuation allowance against our net domestic deferred income tax assets.
	We periodically assess whether it is more likely than not that we will generate sufficient taxable income to realize our deferred income tax assets. We establish valuation allowances if it is not likely we will realize our deferred income tax assets. In making this determination, we consider all available positive and negative evidence and make certain assumptions. We consider, among other things, our deferred tax liabilities, the overall business environment, our historical financial results, our industry’s historically cyclical financial results and potential current and future tax planning strategies.
	During the first quarter of 2014, we moved from a cumulative loss position over the previous three years to a cumulative income position for the first time since we established the full valuation allowance. While this is positive evidence, we have concluded as of September 30, 2014 that the valuation allowance was still needed on our net domestic deferred tax assets based upon the weight of the factors described above, especially considering our history that included six consecutive years of losses. We continue to evaluate our cumulative income position and income trend as well as our future projections of sustained profitability. We evaluate whether this profitability trend constitutes sufficient positive evidence to support a reversal of our valuation allowance (in full or in part). If this profitability trend continues for the remainder of 2014 and this level of profitability is projected in the future, we anticipate that we may reverse substantially all of our domestic valuation allowance as early as the end of 2014.

Actavis_contract_termination

Actavis contract termination	9 Months Ended
	Sep. 30, 2014
Actavis contract termination	'
	Note 17. Actavis contract termination:
	In March 2013, we agreed with Actavis, LLC (“Actavis”), a contract manufacturer of the Company, to terminate our development, manufacturing and supply agreement, effective December 31, 2014. As consideration for the termination of the agreement, we received a greater percentage of the net profit from sales of products during the remaining term of the agreement and a one-time, non-refundable payment of $5,000, which is not subject to future performance. This payment is included in Termination fee in our condensed consolidated statement of operations for the nine months ended September 30, 2013.

Commitments_and_contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and contingencies	'
	Note 18. Commitments and contingencies:
	Litigation
	From time to time, we are subject to claims and litigation arising in the ordinary course of business. These claims may include assertions that our products infringe existing patents and claims that the use of our products has caused personal injuries. We intend to vigorously defend any such litigation that may arise under all defenses that would be available to us.
	Zoledronic Acid (Generic versions of Zometa® and Reclast®). On February 20, 2013, Novartis Pharmaceuticals Corporation (“Novartis”) sued the Company and several other defendants in the United States District Court for the District of New Jersey (Novartis Pharmaceuticals Corporation v. Actavis, LLC, et. al., Case No. 13-cv-1028), alleging, among other things, that sales of the Company’s (i) zoledronic acid premix bag (4mg/100ml), made by ACS Dobfar Info S.A. (“Info”), also a defendant, a generic version of Novartis’ Zometa® ready to use bottle, would infringe U.S. Patent No. 7,932,241 (the “241 Patent”) and U.S. Patent No. 8,324,189 (the “189 Patent”) and (ii) zoledronic acid premix bag (5mg/100ml), also made by Info, a generic version of Novartis’ Reclast® ready to use bottle, would infringe U.S. Patent No. 8,052,987 and the 241 Patent, and (iii) zoledronic acid vial (4mg/5ml), made by Actavis LLC, also a defendant, a generic version of Novartis’ Zometa® vial, would infringe the 189 Patent. On March 1, 2013, the District Court denied Novartis’ request for a temporary restraining order and a preliminary injunction against the Company and the other defendants, including Actavis and Info.
	As of March 6, 2013, the Company, began selling Actavis’ zoledronic acid vial product, a generic version of Zometa® and as of August 27, 2013 and October 1, 2013, the Company began selling zoledronic acid premix bags in 4mg/100ml and 5mg/100ml presentations, respectively.
	The Company believes it has substantial meritorious defenses to the case, and the Company has sold and will continue to sell these products. While an estimate of the potential loss resulting from an adverse final determination that one of the patents in suit is valid and infringed cannot currently be made as specific monetary damages have not been asserted, an adverse final determination could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.
	At this time, there are no other proceedings of which we are aware that are considered likely to have a material adverse effect on the consolidated financial position or results of operations.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events	'
	Note 19: Subsequent Events
	Omega Acquisition
	On October 1, 2014, we and our newly formed, wholly-owned subsidiary, Sagent Acquisition Corp., a Canadian company (“Acquisition Corp”) entered into a Share Purchase Agreement (the “SPA”) with the several shareholders (the “Sellers”) of Omega, a privately held Canadian pharmaceutical and specialty healthcare products company. Pursuant to the SPA, Acquisition Corp acquired all of the issued and outstanding shares of the capital stock of Omega in exchange for approximately $85.3 million (C$95.0 million). The final purchase price is subject to post-closing adjustments for working capital, indebtedness and cash outlays related to Omega’s capital expansion project as provided in the SPA, which at closing were estimated to be C$2.0 million at closing, resulting in a net cash consideration paid at closing of $83.2 million (C$93.0 million). The cash consideration payable at closing was funded by us from available cash on hand.
	The initial accounting for this acquisition, which is subject to fair market valuations which were impractical to complete, will be completed in the fourth quarter of fiscal 2014, and is expected to result in the recognition of intangible assets and goodwill. We expect that Omega will be reported as a separate reportable segment in our consolidated financial statements beginning with the fourth quarter of 2014.
	Revolving credit facility
	On October 31, 2014, we entered into a credit agreement with JPMorgan Chase Bank, N.A., (the “Chase Agreement”). The Chase Agreement provides for an $80,000 asset based revolving credit loan facility, with availability subject to a borrowing base consisting of eligible cash, short-term investments, accounts receivable and inventory and the satisfaction of conditions precedent specified in the Chase Agreement. The Chase Agreement provides for an accordion feature, whereby we may increase the revolving commitment up to an additional $25,000, subject to certain customary terms and conditions, including pro-forma compliance with a fixed charge coverage ratio (as defined in the Chase Agreement) of 1.00 to 1. 00. The Chase Agreement matures on October 31, 2019, at which time all amounts outstanding will be due and payable. Borrowings under the Chase Agreement may be used for general corporate purposes, including funding working capital. Amounts drawn bear an interest rate equal to, at our option, either a Eurodollar rate plus 2.00% per annum or an alternative base rate plus 1.00% per annum. We also incur a commitment fee on undrawn amounts equal to 0.25% per annum.
	The Chase Agreement is guaranteed by our parent company at the time of closing and is secured by a lien on substantially all of our parent company and our principal domestic subsidiary’s assets and any future domestic subsidiary’s guarantor’s assets. The same assets may also be used to secure, and we may guaranty, a loan by an affiliate of JPMorgan Chase Bank, N.A. to our Chinese subsidiary for the construction of a new manufacturing line. The Chase Agreement includes customary covenants and also imposes a financial covenant requiring compliance with a minimum fixed charge coverage ratio of 1.00 to 1.00 during certain covenant testing times triggered if availability under the Chase Agreement is below the greater of 10% of the revolving commitment and $8,000.
	Concurrent with entering the Chase Agreement, we terminated our existing revolving credit facility through Silicon Valley Bank, and repaid certain associated fees. Included with the fees was $1,050 of early termination fees that had previously been deferred by Silicon Valley Bank as part of entering their revolving credit facility in February 2012. This amount will be included within interest expense in the condensed consolidated statement of operations in the fourth quarter of 2014. Concurrent with the repayment and termination of the agreement, all liens and security interests against our property that secured the obligations under our existing revolving credit facility were released and discharged. Loans under the Chase Agreement are secured by a lien on substantially all of our and our principal domestic operating subsidiary’s assets.

Acquisition_Tables

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2014
Consolidated Pro Forma Operations Results in Acquisitions	'
	The pro forma information includes acquisition and integration expenses. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.
		Three Months Ended		Nine Months Ended
		September 30, 2013		September 30, 2013
	Net revenue	$	60,842	$	180,644
	Net income		2,826		19,405
	Diluted income per common share		0.1		0.67

Investments_Tables

Investments (Tables)	9 Months Ended
	Sep. 30, 2014
Investments	'
	Our investments at September 30, 2014 were comprised of the following:
		Cost basis		Unrealized			Unrealized			Recorded		Cash and		Short term
				gains			losses			basis		cash		investments
												equivalents
	Assets
	Cash	$	123,647	$	—		$	—		$	123,647	$	123,647	$	—
	Money market funds		12,633		—			—			12,633		12,633		—
	Commercial paper		5,530		—			—			5,530		—		5,530
	Corporate bonds and notes		13,496		1			(32	)		13,465		—		13,465
		$	155,306	$	1		$	(32	)	$	155,275	$	136,280	$	18,995
Investments with Continuous Unrealized Losses for Less Than Twelve Months and Related Fair Values	'
	Investments with continuous unrealized losses for less than twelve months and their related fair values at September 30, 2014 were as follows:
		Fair value		Unrealized
				losses
	Corporate bonds and notes	$	11,355	$	(32	)
	Commercial paper		2,530		—
		$	13,885	$	(32	)
Cost and Estimated Current Fair Value of Fixed-Income Securities	'
	The original cost and estimated current fair value of our fixed-income securities at September 30, 2014 are set forth below.
		Cost basis		Estimated fair
				value
	Due in one year or less	$	9,670	$	9,671
	Due between one and five years		9,356		9,324
		$	19,026	$	18,995

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Valuation	'
	Inventories at September 30, 2014 and December 31, 2013 were as follows:
		September 30, 2014								December 31, 2013
		Approved			Pending		Inventory			Approved			Pending			Inventory
					regulatory								regulatory
					approval								approval
	Finished goods	$	40,136		$	—	$	40,136		$	44,510		$	1,437		$	45,947
	Raw materials		5,305			2,803		8,108			5,614			19			5,633
	Inventory reserve		(4,943	)		—		(4,943	)		(3,662	)		(1,437	)		(5,099	)
		$	40,498		$	2,803	$	43,301		$	46,462		$	19		$	46,481

Property_plant_and_equipment_T

Property, plant and equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment	'
	Property, plant and equipment at September 30, 2014 and December 31, 2013 were as follows:
		September 30,			December 31,
		2014			2013
	Land and land improvements	$	2,215		$	2,235
	Buildings and improvements		19,519			19,696
	Machinery, equipment, furniture and fixtures		38,447			38,000
	Construction in process		2,558			460
			62,739			60,391
	Less accumulated depreciation		(5,880	)		(2,707	)
		$	56,859		$	57,684

Goodwill_and_Intangible_assets1

Goodwill and Intangible assets, net (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Intangible Assets - Indefinite Lived	'
	Intangible assets at September 30, 2014 and December 31, 2013 were as follows:
		September 30, 2014								December 31, 2013
		Gross carrying			Accumulated			Intangible		Gross carrying		Accumulated			Intangible
		amount			amortization			assets, net		amount		amortization			assets, net
	Product licensing rights	$	6,748		$	(2,750	)	$	3,998	$	5,941	$	(2,087	)	$	3,854
	Product development rights		3,832			—			3,832		3,252		—			3,252
	Total definite-lived intangible assets	$	10,580		$	(2,750	)	$	7,830	$	9,193	$	(2,087	)	$	7,106
	In-process research and development (IPR&D)	$	1,220		$	—		$	1,220	$	1,220	$	—		$	1,220
	Total intangible assets	$	11,800		$	(2,750	)	$	9,050	$	10,413	$	(2,087	)	$	8,326
Schedule of Intangible Assets - Finite lived	'
	Intangible assets at September 30, 2014 and December 31, 2013 were as follows:
		September 30, 2014								December 31, 2013
		Gross carrying			Accumulated			Intangible		Gross carrying		Accumulated			Intangible
		amount			amortization			assets, net		amount		amortization			assets, net
	Product licensing rights	$	6,748		$	(2,750	)	$	3,998	$	5,941	$	(2,087	)	$	3,854
	Product development rights		3,832			—			3,832		3,252		—			3,252
	Total definite-lived intangible assets	$	10,580		$	(2,750	)	$	7,830	$	9,193	$	(2,087	)	$	7,106
	In-process research and development (IPR&D)	$	1,220		$	—		$	1,220	$	1,220	$	—		$	1,220
	Total intangible assets	$	11,800		$	(2,750	)	$	9,050	$	10,413	$	(2,087	)	$	8,326
Changes in Intangible Assets	'
	Changes in intangible assets were due to the following:
		Product			Product			IPR&D
		licensing			development
		rights			rights
	December 31, 2013	$	3,854		$	3,252		$	1,220
	Purchase of product rights		810			2,053			—
	Amortization of product rights		(666	)		(1,473	)		—
	September 30, 2014	$	3,998		$	3,832		$	1,220
Schedule of Estimate Amortization Expense over Each of the Next Five Years	'
	We currently estimate amortization expense over each of the next five years as follows:
		Amortization
		expense
	For the year ending:
	September 30, 2015	$	4,512
	September 30, 2016	$	693
	September 30, 2017	$	609
	September 30, 2018	$	600
	September 30, 2019	$	533

Investment_Tables

Investment (Tables) (Sagent Agila LLC)	9 Months Ended
	Sep. 30, 2014
Sagent Agila LLC	'
Changes in Investment	'
	Changes in our investment in Sagent Agila during the nine months ended September 30, 2014 were as follows:
	Investment in Sagent Agila at January 1, 2014	$	2,063
	Equity in net income of Sagent Agila		2,476
	Investment in Sagent Agila at September 30, 2014	$	4,539
Condensed Statement of Operations Information	'
	Condensed statement of operations information of Sagent Agila is presented below.
		Three Months Ended September 30,				Nine Months Ended September 30,
	Condensed statement of operations information	2014		2013		2014		2013
	Net revenues	$	1,516	$	3,212	$	6,249	$	13,924
	Gross profit		1,473		1,093		4,992		3,817
	Net income		1,473		969		4,952		3,413

Accrued_liabilities_Tables

Accrued liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities	'
	Accrued liabilities at September 30, 2014 and December 31, 2013 were as follows:
		September 30,		December 31,
		2014		2013
	Payroll and employee benefits	$	5,595	$	6,224
	Sales and marketing		5,015		5,305
	Taxes payable		1,564		895
	Other accrued liabilities		1,963		1,507
		$	14,137	$	13,931

Fair_value_measurements_Tables

Fair value measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	Assets measured at fair value on a recurring basis as of September 30, 2014 consisted of the following:
		Total fair value			Quoted prices in		Significant other		Significant
					active markets		observable		unobservable
					for identical		inputs (Level 2)		inputs
					assets (Level 1)				(Level 3)
	Assets
	Money market funds	$	12,633		$	12,633	$	—	$	—
	Corporate bonds and notes		13,465			—		13,465		—
	Commercial paper		5,530			—		5,530		—
	Short-term investments	$	18,995		$	—	$	18,995	$	—
	Total assets	$	31,628		$	12,633	$	18,995	$	—
	Liabilities
	Contingent purchase consideration	$	—		$	—	$	—	$	—
	Assets measured at fair value on a recurring basis as of December 31, 2013 consisted of the following:
		Total fair value			Quoted prices in		Significant other		Significant
					active markets		observable		unobservable
					for identical		inputs (Level 2)		inputs
					assets (Level 1)				(Level 3)
	Assets
	Money market funds	$	11,592		$	11,592	$	—	$	—
	Corporate bonds and notes		92,516			—		92,516		—
	Commercial paper		21,294			—		21,294		—
	Short-term investments	$	113,810		$	—	$	113,810	$	—
	Total assets	$	125,402		$	11,592	$	113,810	$	—
	Liabilities
	Contingent purchase consideration	$	200		$	—	$	—	$	200
Summary of Fair Value of Preferred Stock Warrants Measured Using Significant Unobservable Inputs	'
	Changes in the fair value of our contingent purchase consideration measured using significant unobservable inputs (Level 3), during the nine months ending September 30, 2014 were as follows:
	Balance at January 1, 2014	$	200
	Issuance of contingent purchase consideration		—
	Change in fair value of contingent purchase consideration		(200	)
	Payment of contingent purchase consideration		—
	Balance at September 30, 2014	$	—

Accumulated_other_comprehensiv1

Accumulated other comprehensive income (Tables)	9 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income	'
	Accumulated other comprehensive income at September 30, 2014 and December 31, 2013 is comprised of the following:
		September 30,			December 31,
		2014			2013
	Currency translation adjustment, net of tax	$	48		$	496
	Unrealized gains (losses) on available for sale securities, net of tax		(31	)		(9	)
	Total accumulated other comprehensive income	$	17		$	487

Earnings_per_share_Tables

Earnings per share (Tables)	9 Months Ended
	Sep. 30, 2014
Anti-Dilutive Share Excluded from Calculation of Diluted Earnings per Share	'
	Because of their anti-dilutive effect, the following common share equivalents, comprised of restricted stock and unexercised stock options, have been excluded from the calculation of diluted earnings per share for the three and nine month periods ended September 30, 2014 and 2013, respectively:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Anti-dilutive shares (in thousands)		435		923		1,124		1,212
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	'
	The table below presents the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Basic and dilutive numerator:
	Net income, as reported	$	1,926	$	2,826	$	10,114	$	26,034
	Denominator:
	Weighted-average common shares outstanding - basic (in thousands)		31,895		28,745		31,861		28,349
	Net effect of dilutive securities:
	Stock options and restricted stock		1,065		823		887		702
	Weighted-average common shares outstanding - diluted (in thousands)		32,960		29,568		32,748		29,051
	Net income per common share (basic)	$	0.06	$	0.1	$	0.32	$	0.92
	Net income per common share (diluted)	$	0.06	$	0.1	$	0.31	$	0.9

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Change in Stock Options, Restricted Stock Units (RSUs) and Restricted Stock Awards (RSAs)	'
	The table below presents the change in stock options, restricted stock units (RSUs) and restricted stock awards (RSAs) for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Stock options (in thousands):
	Stock options granted		2		5		261		380
	Stock options exercised		16		29		90		96
	Aggregate intrinsic value of stock options exercised (in thousands)	$	319	$	489	$	1,522	$	1,225
	Restricted Stock Units (RSUs) (in thousands):
	RSUs granted		—		—		19		15
	Restricted Stock Awards (RSAs) (in thousands):
	RSAs granted		—		—		48		42

Net_Revenue_by_Product_Tables

Net Revenue by Product (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Net Revenue by Therapeutic Class	'
	Net revenue by product line is as follows:
		Three Months Ended September 30,				Nine Months Ended September 30,
	Therapeutic class:	2014		2013		2014		2013
	Anti-infective	$	21,370	$	24,026	$	74,896	$	65,921
	Critical care		21,530		15,638		62,153		48,381
	Oncology		22,459		21,178		68,373		66,342
		$	65,359	$	60,842	$	205,422	$	180,644

Basis_of_presentation_Addition

Basis of presentation - Additional Information (Detail)	Sep. 30, 2014	Jun. 30, 2013
	Sagent Agila LLC	KSCP
Basis of Presentation [Line Items]	'	'
Joint venture, ownership interest percentage	50.00%	'
Percentage of remaining equity interest acquired	'	50.00%

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	9 Months Ended			0 Months Ended	9 Months Ended		0 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Jun. 04, 2013	Sep. 30, 2014	Jun. 04, 2013	Dec. 12, 2013
				SCP	SCP	SCP	Mylan Inc
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Percentage of remaining equity interest acquired	'	'	'	'	'	50.00%	'
Business acquisition, purchase price	'	'	'	$25,000	'	'	$3,400
Cash	'	'	'	'	'	2,704	'
Inventory	'	'	'	'	'	2,396	'
Prepaid assets	'	'	'	'	'	196	'
Property, plant and equipment	'	'	'	'	'	56,654	'
Long term bank loans	'	'	'	'	'	19,095	'
Accrued compensation and other liabilities	'	'	'	'	'	8,954	'
Goodwill	6,038	'	6,038	'	'	6,038	'
Acquisition related installment payment made	3,500	7,296	'	'	3,500	'	'
Acquisition related remaining installment due in next year	'	'	'	'	9,000	'	'
Business acquisition, gross consideration paid	'	'	'	'	'	'	3,200
Contingent consideration	'	'	'	'	'	'	$200

Consolidated_Pro_Forma_Operati

Consolidated Pro Forma Operations Results in Acquisitions (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Business Acquisition [Line Items]	'	'
Net revenue	$60,842	$180,644
Net income	$2,826	$19,405
Diluted income per common share	$0.10	$0.67

Investments_Detail

Investments (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cost basis	$155,306	'	'	'
Unrealized gains	1	'	'	'
Unrealized losses	-32	'	'	'
Recorded basis	155,275	'	'	'
Cash and cash equivalents	136,280	42,332	45,937	27,687
Short term investments	18,995	113,810	'	'
Cash	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cost basis	123,647	'	'	'
Recorded basis	123,647	'	'	'
Cash and cash equivalents	123,647	'	'	'
Money market funds	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cost basis	12,633	'	'	'
Recorded basis	12,633	'	'	'
Cash and cash equivalents	12,633	'	'	'
Commercial paper	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cost basis	5,530	'	'	'
Recorded basis	5,530	'	'	'
Short term investments	5,530	'	'	'
Corporate bonds and notes	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cost basis	13,496	'	'	'
Unrealized gains	1	'	'	'
Unrealized losses	-32	'	'	'
Recorded basis	13,465	'	'	'
Short term investments	$13,465	'	'	'

Investments_with_Continuous_Un

Investments with Continuous Unrealized Losses for Less Than Twelve Months and Related Fair Values (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'
Fair value	$13,885
Unrealized losses	-32
Corporate bonds and notes	'
Schedule of Available-for-sale Securities [Line Items]	'
Fair value	11,355
Unrealized losses	-32
Commercial paper	'
Schedule of Available-for-sale Securities [Line Items]	'
Fair value	$2,530

Cost_and_Estimated_Current_Fai

Cost and Estimated Current Fair Value of Fixed-Income Securities (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'
Due in one year or less, cost basis	$9,670
Due between one and five years, cost basis	9,356
Total fixed income securities, cost basis	19,026
Due in one year or less, Estimated fair value	9,671
Due between one and five years, Estimated fair value	9,324
Total fixed income securities, Estimated fair value	$18,995

Inventories_Detail

Inventories (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Finished goods	$40,136	$45,947
Raw materials	8,108	5,633
Inventory reserve	-4,943	-5,099
Inventory, Net, Total	43,301	46,481
Approved	'	'
Inventory [Line Items]	'	'
Finished goods	40,136	44,510
Raw materials	5,305	5,614
Inventory reserve	-4,943	-3,662
Inventory, Net, Total	40,498	46,462
Pending Regulatory Approval	'	'
Inventory [Line Items]	'	'
Finished goods	'	1,437
Raw materials	2,803	19
Inventory reserve	'	-1,437
Inventory, Net, Total	$2,803	$19

Property_Plant_and_Equipment_D

Property Plant and Equipment (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment before depreciation	$62,739	$60,391
Less accumulated depreciation	-5,880	-2,707
Property Plant and equipment after depreciation	56,859	57,684
Land and Land Improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment before depreciation	2,215	2,235
Buildings and improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment before depreciation	19,519	19,696
Machinery, equipment, furniture, and fixtures	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment before depreciation	38,447	38,000
Construction in process	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment before depreciation	$2,558	$460

Property_Plant_and_Equipment_A

Property Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Property, Plant and Equipment [Line Items]	'	'
Depreciation expense	$701	$2,698

Goodwill_and_Intangible_assets2

Goodwill and Intangible assets, net - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
		Right
Finite-Lived Intangible Assets [Line Items]	'	'	'
Goodwill acquired	'	$6,038,000	$6,038,000
Goodwill impairment	$0	$0	'
Number of products	'	27	'
Product Licensing Rights	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Weighted-average period prior to next extension or renewal of intangible asset	'	'69 months	'

Schedule_of_Intangible_Assets_

Schedule of Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Definite-lived intangible assets, Gross carrying amount	$10,580	$9,193
Definite-lived intangible assets, Accumulated amortization	-2,750	-2,087
Definite-lived intangible assets, net	7,830	7,106
Intangible assets, Gross carrying amount	11,800	10,413
Intangible assets, Accumulated amortization	-2,750	-2,087
Intangible assets, net	9,050	8,326
Product Licensing Rights	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Definite-lived intangible assets, Gross carrying amount	6,748	5,941
Definite-lived intangible assets, Accumulated amortization	-2,750	-2,087
Definite-lived intangible assets, net	3,998	3,854
Intangible assets, Accumulated amortization	-666	'
Product Development Rights	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Definite-lived intangible assets, Gross carrying amount	3,832	3,252
Definite-lived intangible assets, net	3,832	3,252
Intangible assets, Accumulated amortization	-1,473	'
IPR&D	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Indefinite-lived IPR&D, Gross carrying amount	1,220	1,220
Indefinite-lived IPR&D, Accumulated amortization	'	'
Indefinite-lived IPR&D, Intangible assets, net	$1,220	$1,220

Changes_in_Intangible_Assets_D

Changes in Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Intangible Assets Disclosure [Line Items]	'	'
Beginning Balance	$7,106	'
Amortization of product rights	-2,750	-2,087
Ending Balance	7,830	7,106
IPR&D	'	'
Intangible Assets Disclosure [Line Items]	'	'
Beginning Balance	1,220	'
Purchase of product rights	'	'
Amortization of product rights	'	'
Ending Balance	1,220	'
Product Licensing Rights	'	'
Intangible Assets Disclosure [Line Items]	'	'
Beginning Balance	3,854	'
Purchase of product rights	810	'
Amortization of product rights	-666	'
Ending Balance	3,998	'
Product Development Rights	'	'
Intangible Assets Disclosure [Line Items]	'	'
Beginning Balance	3,252	'
Purchase of product rights	2,053	'
Amortization of product rights	-1,473	'
Ending Balance	$3,832	'

Schedule_of_Estimate_Amortizat

Schedule of Estimate Amortization Expense over Each of the Next Five Years (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'
For the year ending September 30, 2015	$4,512
For the year ending September 30, 2016	693
For the year ending September 30, 2017	609
For the year ending September 30, 2018	600
For the year ending September 30, 2019	$533

Changes_in_Investment_of_Sagen

Changes in Investment of Sagent Agila (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Investment at beginning of the period	'	'	$2,063	'
Equity in net loss (income) of joint ventures	-737	-485	-2,476	118
Investment at end of the period	4,539	'	4,539	'
Sagent Agila LLC	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Investment at beginning of the period	'	'	2,063	'
Equity in net loss (income) of joint ventures	'	'	2,476	'
Investment at end of the period	$4,539	'	$4,539	'

Condensed_Statement_of_Operati

Condensed Statement of Operations Information (Detail) (Sagent Agila LLC, USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Sagent Agila LLC	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'
Net revenues	$1,516	$3,212	$6,249	$13,924
Gross profit	1,473	1,093	4,992	3,817
Net income	$1,473	$969	$4,952	$3,413

Debt_Additional_Information_De

Debt - Additional Information (Detail)	0 Months Ended		9 Months Ended
	Jan. 02, 2014	Jan. 02, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Jun. 04, 2013	Jun. 04, 2013	Jun. 04, 2013	Jun. 04, 2013
	USD ($)	CNY		USD ($)	CNY	Loan Contract One	Loan Contract One	Loan Contract Two	Loan Contract Two
						USD ($)	CNY	USD ($)	CNY
Line of Credit Facility [Line Items]	'	'	'	'	'	'	'	'	'
Loan contracts assumed in a business combination	'	'	'	'	'	$6,069,000	37,000,000	$13,613,000	83,000,000
Period of loan contract	'	'	'5 years	'	'	'	'	'	'
Outstanding ABC loan amount	'	'	'	10,333,000	63,000,000	'	'	'	'
Repayment of ABC loan	10,333,000	63,000,000	'	'	'	'	'	'	'
Early termination fees	$0	0	'	'	'	'	'	'	'

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Line Items]	'	'
Payroll and employee benefits	$5,595	$6,224
Sales and marketing	5,015	5,305
Taxes payable	1,564	895
Other accrued liabilities	1,963	1,507
Accrued Liabilities, Total	$14,137	$13,931

Summary_of_Assets_Measured_at_

Summary of Assets Measured at Fair Value on Recurring Basis (Detail) (Assets measured at fair value on a recurring basis, USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	$31,628	$125,402
Contingent purchase consideration	'	200
Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	12,633	11,592
Corporate bonds and notes	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	13,465	92,516
Commercial paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	5,530	21,294
Short-term investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	18,995	113,810
Quoted prices in active markets for identical assets (Level 1)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	12,633	11,592
Quoted prices in active markets for identical assets (Level 1) | Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	12,633	11,592
Significant other observable inputs (Level 2)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	18,995	113,810
Significant other observable inputs (Level 2) | Corporate bonds and notes	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	13,465	92,516
Significant other observable inputs (Level 2) | Commercial paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	5,530	21,294
Significant other observable inputs (Level 2) | Short-term investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	18,995	113,810
Significant unobservable inputs (Level 3)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent purchase consideration	'	$200

Summary_of_Fair_Value_of_Prefe

Summary of Fair Value of Preferred Stock Warrants Measured Using Significant Unobservable Inputs (Detail) (Contingent Consideration Liability, USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Contingent Consideration Liability	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Balance at beginning of period	$200
Issuance of contingent purchase consideration	'
Change in fair value of contingent purchase consideration	-200
Payment of contingent purchase consideration	'
Balance at end of period	$0

Recovered_Sheet1

Accumulated Other Comprehensive Income (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Currency translation adjustment, net of tax	$48	$496
Unrealized gains (losses) on available for sale securities, net of tax	-31	-9
Total accumulated other comprehensive income	$17	$487

Recovered_Sheet2

Accumulated Other Comprehensive Income - Additional Information (Detail) (Reclassification out of Accumulated Other Comprehensive Income, USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Reclassification out of Accumulated Other Comprehensive Income	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Realized losses on available for sale securities	$49	$49

AntiDilutive_Share_Excluded_fr

Anti-Dilutive Share Excluded from Calculation of Diluted Earnings per Share (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive shares	435	923	1,124	1,212

Schedule_of_Calculation_of_Num

Schedule of Calculation of Numerator and Denominator in Earnings Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Basic and dilutive numerator	'	'	'	'
Net income, as reported	$1,926	$2,826	$10,114	$26,034
Denominator	'	'	'	'
Weighted-average common shares outstanding - basic (in thousands)	31,895	28,745	31,861	28,349
Net effect of dilutive securities Stock options and restricted stock	1,065	823	887	702
Weighted-average common shares outstanding - diluted (in thousands)	32,960	29,568	32,748	29,051
Net income per common share (basic)	$0.06	$0.10	$0.32	$0.92
Net income per common share (diluted)	$0.06	$0.10	$0.31	$0.90

Schedule_of_Change_in_Stock_Op

Schedule of Change in Stock Options, Restricted Stock Units (RSUs) and Restricted Stock Awards (RSAs) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock options granted	2	5	261	380
Stock options exercised	16	29	90	96
Aggregate intrinsic value of stock options exercised	$319	$489	$1,522	$1,225
Restricted Stock Units (RSUs)	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Restricted stock granted	'	'	19	15
Restricted Stock Awards (RSAs)	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Restricted stock granted	'	'	48	42

Schedule_of_Net_Amount_of_Risk

Schedule of Net Amount of Risk by Product and Guarantee (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Product Information [Line Items]	'	'	'	'
Net revenue by Product Line	$65,359	$60,842	$205,422	$180,644
Anti-infective	'	'	'	'
Product Information [Line Items]	'	'	'	'
Net revenue by Product Line	21,370	24,026	74,896	65,921
Critical care	'	'	'	'
Product Information [Line Items]	'	'	'	'
Net revenue by Product Line	21,530	15,638	62,153	48,381
Oncology	'	'	'	'
Product Information [Line Items]	'	'	'	'
Net revenue by Product Line	$22,459	$21,178	$68,373	$66,342

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
		Sagent Agila LLC	Sagent Agila LLC
Related Party Transaction [Line Items]	'	'	'
Receivables from related party	'	$2,716,000	$3,644,000
Payable for the acquisition of inventory	'	7,528,000	3,129,000
Distributed profit sharing receipts to joint venture partners	$1,995,000	$0	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Income Tax Disclosure [Line Items]	'	'
Provision for income taxes	$1,387	$2,774
Valuation allowance	25,000	25,000
Alternative Minimum Tax	'	'
Income Tax Disclosure [Line Items]	'	'
Provision for income taxes	$933	$933

Actavis_Contract_Termination_A

Actavis Contract Termination - Additional Information (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Development, manufacturing and supply agreement, one time payment for termination	'	$5,000
Actavis	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Development, manufacturing and supply agreement, effective termination date	31-Dec-14	'
Development, manufacturing and supply agreement, one time payment for termination	'	$5,000

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Event)	0 Months Ended			0 Months Ended			0 Months Ended
	Oct. 01, 2014	Oct. 01, 2014	Oct. 01, 2014	Oct. 31, 2014	Oct. 31, 2014	Oct. 31, 2014	Oct. 31, 2014	Oct. 31, 2014	Oct. 31, 2014	Oct. 31, 2014
	USD ($)	CAD	CAD	JPMorgan Chase Bank, N.A.	JPMorgan Chase Bank, N.A.	JPMorgan Chase Bank, N.A.	JPMorgan Chase Bank, N.A.	JPMorgan Chase Bank, N.A.	JPMorgan Chase Bank, N.A.	SVB Agreement
				Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility
					USD ($)	Maximum	Minimum	Eurodollar	Base Rate	USD ($)
						USD ($)	USD ($)
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'	'
Cash paid for acquiring of issued and outstanding shares of capital stock	$85,300,000	95,000,000	'	'	'	'	'	'	'	'
Post-closing adjustments	'	'	2,000,000	'	'	'	'	'	'	'
Business acquisition, purchase price	83,200,000	93,000,000	'	'	'	'	'	'	'	'
Amount available under revolving credit loan facility	'	'	'	'	80,000,000	'	'	'	'	'
Additional amount available under revolving credit loan facility	'	'	'	'	'	25,000,000	'	'	'	'
Fixed charge coverage ratio	'	'	'	'	100.00%	'	'	'	'	'
Revolving credit facility, covenants description	'	'	'	'The Chase Agreement includes customary covenants and also imposes a financial covenant requiring compliance with a minimum fixed charge coverage ratio of 1.00 to 1.00 during certain covenant testing times triggered if availability under the Chase Agreement is below the greater of 10% of the revolving commitment and $8,000.	'	'	'	'	'	'
Threshold to trigger financial covenant, percentage	'	'	'	'	'	'	10.00%	'	'	'
Threshold to trigger financial covenant, amount	'	'	'	'	'	'	8,000	'	'	'
Agreement maturity date	'	'	'	31-Oct-19	'	'	'	'	'	'
Basis Spread on Variable Rate	'	'	'	'	'	'	'	2.00%	1.00%	'
Commitment fee on undrawn amounts	'	'	'	0.25%	'	'	'	'	'	'
Early termination fees	'	'	'	'	'	'	'	'	'	$1,050,000